INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Sep 30, 2008 |
SVP, Research & Devel Sciences
|
SVP, Research & Devel Sciences | Form 4 | Open market or private sale of non-derivative or derivative security | 3,053 | $21.50 | 550 |
| Oct 31, 2006 |
SVP, Therap & Clin Prog Dev
|
SVP, Therap & Clin Prog Dev | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 1,400 | -- | 648 |
| Jan 05, 2005 |
SVP, PreclinDevel & Biomol Sci
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 1,600 | -- | 1,600 |
| Dec 16, 2011 |
SVP Research and Development S
|
SVP Research and Development S | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 1,921 | -- | 1,921 |
| Oct 31, 2006 |
SVP, Therap & Clin Prog Dev
|
SVP, Therap & Clin Prog Dev | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 200 | -- | 2,048 |
| Oct 31, 2006 |
SVP, Therap & Clin Prog Dev
|
SVP, Therap & Clin Prog Dev | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 700 | -- | 2,248 |
| May 25, 2018 |
EVP Research and Development
|
EVP Research and Development | Form 4 | Other acquisition or disposition | -- | -- | 2,317 |
| Jul 27, 2009 |
SVP Res and Dev Sciences
|
SVP Res and Dev Sciences | Form 4 | Open market or private sale of non-derivative or derivative security | 24,686 | $20.74 | 2,550 |
| Oct 31, 2006 |
SVP, Therap & Clin Prog Dev
|
SVP, Therap & Clin Prog Dev | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 300 | -- | 2,948 |
| Dec 08, 2023 |
EVP Research and Development
|
EVP Research and Development | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 3,059 | -- | 3,059 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.